{
  "slug": "epad-european-prevention-of-alzheimer-s-dementia-spain-eu-uk",
  "name": "Epad European Prevention Of Alzheimer S Dementia Spain Eu Uk",
  "description": "The European Prevention of Alzheimer's Dementia (EPAD) project is an initiative funded by the Innovative Medicines Initiative, established to overcome major hurdles in drug development for the secondary prevention of Alzheimer's dementia. It conducts the EPAD Longitudinal Cohort Study (LCS) and a Bayesian adaptive designed EPAD Proof-of-Concept (PoC) trial. Its core objectives are to build a readiness cohort for the PoC trial and to generate a comprehensive, large dataset for disease modeling of preclinical and prodromal Alzheimer's disease.",
  "url": "https://optimly.ai/brand/epad-european-prevention-of-alzheimer-s-dementia-spain-eu-uk",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/pubmed.ncbi.nlm.nih.gov",
  "baiScore": 48,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Healthcare",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-09T00:02:29.387Z",
  "verifiedVitals": {
    "website": "https://pubmed.ncbi.nlm.nih.gov",
    "founded": "Prior to 2016",
    "headquarters": "Pan-European",
    "pricing_model": "Not applicable; it is a research project funded by grants (e.g., Innovative Medicines Initiative), not a commercial entity with a pricing model.",
    "core_products": "Longitudinal Cohort Study (LCS) for participant characterization and data generation; Proof-of-Concept (PoC) clinical trial for drug development; comprehensive data sets for disease modeling.",
    "key_differentiator": "Pan-European multicentre approach, large-scale longitudinal cohort study focusing on the full continuum of Alzheimer's probability, Bayesian adaptive designed Proof-of-Concept trial, and commitment to generating and disseminating comprehensive data for disease modeling.",
    "target_markets": "Scientific community, research participants, patient community, general public, industry, regulatory authorities, and policy-makers interested in Alzheimer's disease prevention and research.",
    "employee_count": "Not specified in the provided context.",
    "funding_stage": "Research grant-funded (initially by the Innovative Medicines Initiative)",
    "subcategory": "Alzheimer's Disease Research & Prevention"
  },
  "intentTags": {
    "problemIntents": [
      "Individual Academic Research Studies: Researchers conducting smaller-scale, independent studies on Alzheimer's prevention, potentially lacking the pan-European scope, standardized protocols, and large",
      "Contract Research Organizations (CROs): Pharmaceutical companies could contract CROs to run specific clinical trials. However, this lacks the consortium approach of EPAD, which focuses on building a r",
      "Lack of Coordinated European Effort: Without an initiative like EPAD, efforts to overcome drug development hurdles for secondary prevention of Alzheimer's dementia in Europe would remain siloed and le"
    ],
    "solutionIntents": [
      "European Prevention of Alzheimer's Dementia project",
      "EPAD study Alzheimer's",
      "Alzheimer's dementia prevention trials Europe",
      "Innovative Medicines Initiative Alzheimer's"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1786358042496
}